Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Barinthus Biotherapeutics (BRNS) Depreciation & Amortization (CF) (2020 - 2025)

Historic Depreciation & Amortization (CF) for Barinthus Biotherapeutics (BRNS) over the last 6 years, with Q3 2025 value amounting to $901000.0.

  • Barinthus Biotherapeutics' Depreciation & Amortization (CF) fell 3891.53% to $901000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $6.4 million, marking a year-over-year increase of 959.19%. This contributed to the annual value of $5.8 million for FY2024, which is 683.37% up from last year.
  • As of Q3 2025, Barinthus Biotherapeutics' Depreciation & Amortization (CF) stood at $901000.0, which was down 3891.53% from $2.0 million recorded in Q2 2025.
  • Barinthus Biotherapeutics' 5-year Depreciation & Amortization (CF) high stood at $2.0 million for Q1 2025, and its period low was $85000.0 during Q3 2021.
  • Moreover, its 5-year median value for Depreciation & Amortization (CF) was $1.2 million (2023), whereas its average is $1.1 million.
  • In the last 5 years, Barinthus Biotherapeutics' Depreciation & Amortization (CF) soared by 129764.71% in 2022 and then crashed by 3891.53% in 2025.
  • Over the past 5 years, Barinthus Biotherapeutics' Depreciation & Amortization (CF) (Quarter) stood at $321000.0 in 2021, then skyrocketed by 266.67% to $1.2 million in 2022, then increased by 21.92% to $1.4 million in 2023, then dropped by 0.49% to $1.4 million in 2024, then crashed by 36.9% to $901000.0 in 2025.
  • Its Depreciation & Amortization (CF) stands at $901000.0 for Q3 2025, versus $2.0 million for Q2 2025 and $2.0 million for Q1 2025.